GSK

2,055

+0.1%↑

STJ

1,298.5

-2.22%↓

GSK

2,055

+0.1%↑

STJ

1,298.5

-2.22%↓

GSK

2,055

+0.1%↑

STJ

1,298.5

-2.22%↓

GSK

2,055

+0.1%↑

STJ

1,298.5

-2.22%↓

GSK

2,055

+0.1%↑

STJ

1,298.5

-2.22%↓

Search

Hikma Pharmaceuticals PLC

Closed

SectorHealthcare

1,212 0.41

Overview

Share price change

24h

Current

Min

1199

Max

1229

Key metrics

By Trading Economics

Income

165M

Sales

41M

1.7B

P/E

Sector Avg

8.888

61.417

EPS

1.07

Dividend yield

6.95

Profit margin

9.698

Employees

9,400

EBITDA

152M

411M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+58.48% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

6.95%

2.40%

Market Stats

By TradingEconomics

Market Cap

-1B

2.6B

Previous open

1211.59

Previous close

1212

News Sentiment

By Acuity

50%

50%

146 / 351 Ranking in Healthcare

Hikma Pharmaceuticals PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 paź 2025, 08:54 UTC

Major Market Movers

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

8 kwi 2025, 08:20 UTC

Market Talk

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

Peer Comparison

Price change

Hikma Pharmaceuticals PLC Forecast

Price Target

By TipRanks

58.48% upside

12 Months Forecast

Average 1,887.5 GBX  58.48%

High 2,400 GBX

Low 1,350 GBX

Based on 4 Wall Street analysts offering 12 month price targets forHikma Pharmaceuticals PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

3

Buy

0

Hold

1

Sell

Sentiment

By Acuity

146 / 351 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
help-icon Live chat